Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of [177Lu]Lu-NNS309 in advanced solid tumors
NL-OMON60811Phase 1Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label trial of [177Lu]Lu-NNS309 in colorectal cancer (CRC), breast cancer, non-small cell lung cancer (NSCLC) and 1 more (4 cohorts), sponsored by Novartis. Primary endpoints: Safety and Tolerability. Started May 2026; status: recruiting.
02
Drugs
[177Lu]Lu-NNS309
03
Conditions
colorectal cancer (CRC)breast cancernon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON60811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60811.